Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

A therapeutic nanoparticle comprising: at least one oncologic drug; and taurolidine, whereby to provide the simultaneous delivery of the at least one oncologic drug and taurolidine, thereby harnessing the synergistic effect of taurolidine on the at least one oncologic drug.

Described herein, are microneedle devices comprising a recombinant alphavirus replicon encoding an exogenous polypeptide, wherein the recombinant alphavirus replicon is coated onto or embedded into a plurality of microneedles. Also described herein are methods of preparing a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide. Also disclosed herein are methods of inducing an immune response in an individual comprising contacting the individual with a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide.

Disclosed are conjugates, compositions, and methods that include or use one or more gold(III) porphyrin complexes. Preferred conjugates are gold(III) porphyrin-poly(ethylene glycol) (PEG) conjugates. Preferred compositions and methods include or use such gold(III) porphyrin-PEG conjugates. Disclosed is a method for treatment of cancer comprising administering to a human in need of such treatment a composition containing a therapeutically effective amount of gold(III) porphyrin-poly(ethylene glycol) (PEG) conjugates. The gold(III) porphyrin-PEG conjugates can be in the form of nanostructures formed by self-assembly of the gold(III) porphyrin-PEG conjugates; or nanocomposites formed by encapsulation of other therapeutic agents by the nanostructures of gold(III) porphyrin-PEG conjugates.

Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (~100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.

The present invention belongs to the technical field of nanomedicine, and relates to a method for preparing a therapeutic protein-loaded nanoparticle, as well as a therapeutic protein-loaded nanoparticle, a suspension and a pharmaceutical composition comprising the nanoparticle, and a pharmaceutical preparation comprising the nanoparticle, the suspension or the pharmaceutical composition. The present invention further relates to a use of the nanoparticle in manufacture of a pharmaceutical composition, wherein the pharmaceutical composition is useful in prevention or treatment of a disease that can be prevented or treated by the therapeutic protein comprised in the nanoparticle.

The present invention describes a covalent biomaterial which is formed by gelling feruloylated arabinoxylans that are biodegradable and which can be used for the oral administration of insulin directed to the colon. The present invention also relates to a method for producing enzymatically covalently crosslinked particles. The aforementioned pharmaceutical composition is suitable for use in the biomedical or pharmaceutical industry as a non-invasive treatment for the oral administration of insulin or insulin analogs for patients with type 1 diabetes.

The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides and its use for treating cancer.

The present disclosure generally relates to nanoparticles comprising an antibody, such as an anti-PD-1 antibody. Other aspects include methods of making and using such nanoparticles. In an embodiment, the nanoparticles comprise a diblock poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer, a chemotherapeutic agent, and a prostate-specific membrane antigen (PSMA) targeting ligand.

Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.”

The present invention relates to an improved method for producing a colloidal nitrocellulose dispersion made compatible with a system of acrylic monomers polymerized with surfactants in a water-based system under pressure. The self-emulsifiable system of the present invention is characterized by the latex formed by the nitrocellulose suspension in an aqueous medium, with nanometric particles and homogeneity and, consequently, a greater covering and smoothing power, high adherence, high gloss, greater chemical and mechanical resistance, rapid drying, less water retention when used in paints, varnish and sealant compositions for coatings in the fields of graphic printing, such as flexography and rotogravure, lamination, nail polish, metal-mechanics, decoration, glass, leather, plastics, wood surfaces, compounds and mortars, decorative wall paints, textiles, paper coatings and car paint repairs, inter alia . Besides providing high-performance properties, the product according to this invention is environmentally friendly.

Aerosols containing a plurality of aqueous droplets, each droplet containing on average at least one essentially neutral particle sized to fit within the droplet are provided. Aerosols wherein an active pharmaceutical ingredient is attached to, or otherwise incorporated in the essentially neutral particles are also provided. Methods for administering an active pharmaceutical ingredient to a subject in need thereof via inhalation of these aerosols, preferably via nebulizer, are also provided.

A method for the preparation of a delivery drug delivery system, the drug having one or more active pharmaceutical ingredients having solubility in water of less than 1 g in 30 ml of water and nano-diamond, comprises the steps of dissolving the active pharmaceutical ingredient(s) into a polar non-aqueous solvent to form a first mixture, dissolving a surfactant in deionized water to form a surfactant solution, adding a plurality of nano-diamond particles to the surfactant solution to disperse the nano-diamond particles in the surfactant solution thereby forming a nano- diamond dispersion, adding the first mixture to the nano-diamond dispersion whilst agitating the dispersion to form a second mixture; and drying the second mixture to produce a dry powder for use as a drug delivery system.

Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, L, X, L, G1, G2, Z, a1, a2 and n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

本发明涉及纳米药物技术领域，本发明提供了种药物载体、兼具pH响应性和HSC靶向性的载药纳米球、其制备方法和应用，该载药纳米球包括：药物基体，所述药物�x57FA;体为负载喜树碱的介孔中空二氧化硅纳米颗粒；复合在所述药物基体上的偶联物，所述偶联物为视黄醇偶联的壳聚糖。本发明提供的载药纳米球粒径分布均匀、比表面积大，生物相容好；能有效解决喜树碱溶解性差、生物利用度低的问题；对喜树碱的释放具有缓释作用，且在低的pH环境下释放明显高于在偏碱性的生理条件下的释放；并对视黄醇和视黄醇结合蛋白复合高摄取的肝星状细胞具有特异的靶向性，可进步提高喜树碱抗肝纤维化的效果，利于应用。

本发明公开了种基于金属纳米粒子和微凝胶的复合药物载体及其应用，该复合药物载体由贵金属纳米粒子及其附着的热响应聚合物凝胶微球骨架所构成，热响应聚合物凝胶微球骨架为聚(N‑异丙基丙烯酰胺)PNIPAM微球所构成的骨架；贵金属纳米粒子为金纳米球；本发明的载体在药物释放及联合光热治疗上的应用；本发明运用纳米金包裹入侵微凝胶来改变微凝胶的表面化学，构建出复合载药系统，具有良好的生物相容性和高效热响应性，不仅可以达成药物热响应控释，纳米金也能够起到联合光热治疗的作用，达到药物联合治疗的目的。

本发明涉及种共载抗原、MPLA与IMQ的阳离子磷脂‑聚合物杂化纳米粒疫苗佐剂及制备方法与应用，该疫苗佐剂在疏水性内核包载TLR7激动剂咪喹莫特，在磷脂层包载TLR4激动剂单磷酰脂质A，通过磷脂层中的阳离子磷脂DOTAP吸附抗原，通过杂化纳米粒保护抗原并提高树突状细胞对抗原的摄取，通过TLR激动剂显著增强抗原刺激后的免疫应答并显著改善抗原交叉呈递；本发明的杂化纳米粒作为疫苗佐剂能够同时共负载抗原及不同类别的TLR激动剂，能以多种免疫途径递送抗原，促进DC活化与成熟，提高交叉提呈水平，产生强有力的T细胞杀伤效应，诱导细胞因子分泌，产生长效记忆性T细胞反应，对肿瘤有较好的预防能力。

种红细胞膜包裹的纳米磁性颗粒及其制备方法和用途。本发明提供了种红细胞包裹的纳米磁性颗粒。本发明还提供了该纳米磁性颗粒在制备心梗动物模型中的用途。本发明心肌梗死动物模型对心肌梗死的预防、诊断和治疗具有极其重要的价值，本发明跳出以往通过外科手术冠状动脉结扎制备心肌梗死动物模型的思路，构建携磁人工红细胞并回输动物体内，用体外磁场控制携磁人工红细胞的局部聚集导致心脏局部血管阻塞，引发局部心肌梗死。这样完全避免血管结扎造成的重大创伤，得到能真实模拟心肌梗死发生过程的动物模型，对相关研究治疗具有极为重大的意义。

Provided herein are p-GlcNAc nanoparticle/nucleic acid compositions. In one aspect, the p-GlcNAc nanoparticle/nucleic acid compositions comprise deacetylated poly-N- acetylglucosamine lactate derivative nanoparticles less than 500 nm and a nucleic acid. Also, provided herein are methods for administering a nucleic acid to a subject, the method comprising administering to the subject a p-GlcNAc nanoparticle/nucleic acid composition. In certain embodiments, the p-GlcNAc nanoparticle/nucleic acid composition is administered subcutaneous ly to the subject.

本发明公开了种非诺贝特纳米制剂的制备方法，包括：溶解步骤、悬浮液初液制备步骤、悬浮液初液制备步骤、制粒步骤、整粒步骤和压片、包装步骤。本发明制备方法制得的非诺贝特纳米制剂平均粒径小于1μm，而且非诺贝特纳米体系均、稳定，重现性高，而且成本低，利于大范围推广。

种肿瘤靶向的纳米诊疗剂，包括具有空腔和介孔孔道的二氧化硅纳米颗粒和装载于所述二氧化硅纳米颗粒的空腔和介孔孔道中的过渡金属羰基化合物。本发明还提供种肿瘤靶向的纳米诊疗剂的制备方法及其用途。本发明通过真空纳米浇铸法将所述过渡金属羰基化合物装载于所述二氧化硅纳米颗粒内，不仅制备工艺简单、成本低廉，且所述过渡金属羰基化合物的装载效率较高。此外，本发明的纳米诊疗剂具有被动靶向肿瘤输运和在肿瘤部位响应释放CO及CO释放MRI成像监测，因此，本发明的纳米诊疗剂治疗肿瘤是种无创、低毒、绿色的治疗方式。

本发明提供种由聚磷酸酯和聚ε‑己内酯组成的二嵌段共聚物，所述二嵌段共聚物由下式表示，其中聚ε‑己内酯嵌段的聚合度x为15‑186，聚磷酸酯嵌段的聚合度y为7‑200。本发明还提供由所述共聚物组装形成的纳米颗粒，所述纳米颗粒作为药物载体的用途，包含所述纳米颗粒的药物递送系统，以及所述共聚物和纳米颗粒的制备方法。

本发明公开了种载药金纳米枝晶颗粒的制备方法。具体是以金纳米颗粒为种子，制备出亲水性的金纳米枝晶颗粒，再将模式药物装载到金纳米枝晶颗粒表面，制备出种载药金纳米枝晶颗粒，通过近红外光或者pH调控药物的释放。本发明的载药金纳米枝晶颗粒分散性良好，载药性能优越，具有较强的光热转换效应，光热促发的释放性能以及pH响应的释放性能，在药物释放、抗癌疗法等领域有广泛的应用前景。

Resumen de: CN108721605A

本发明公开了种装载有胰岛素的纳米粒子，由葡甘露聚糖、刀豆蛋白A和交联剂进行可逆的交联反应得到。本发明开发出由天然聚合物制备的葡萄糖感应型胰岛素口服纳米粒子，利用该纳米粒子可以构建葡萄糖感应型胰岛素口服输运体系，该体系具有葡萄糖感应性的、可控血糖的、低毒的输运体系的基本特性；在体内应用的效果较好，具有缓慢、较长时间的降糖作用，提高了胰岛素口服输运体系的控血糖疗效，在糖尿病治疗、天然聚合物医疗功能的开发等领域具有较大的应用潜力。